I. Preface
The mammalian gastrointestinal tract is inhabited by a vast and diverse community of microbes 1) and their metabolic activity significantly influences the host's health. In mice, short-chain fatty acids produced by intestinal bacteria have been shown to affect the body weight, energy balance, and immune response 2) , while butyric acid produced by clostridia is known to induce the differentiation of colonic regulatory T cells and also induce the expression of N-acetylglucosamine 6-O-sulfotransferase-2 that modifies mucin-type O-glycans in the gut 3, 4) . Moreover, the presence of certain bacterial metabolites has frequently been associated with the incidence of behavioral abnormalities of the host 5) . It is therefore not exaggerated to consider the intestinal bacterial population as an organ of the host. Hence, it is important to understand what shapes and influences this consortium of intestinal bacteria.
Dietary habits have been assumed to significantly affect the gut microbial composition. This concept is true in most part, because gut microbiomes are shown to vary among communities with different diets 6) and also to change rapidly within individuals when their diets change 7) . Non-digestible glycans in diets are thus the main factor affecting the gut microbial community. The genomes of several gut microbes contain genetic loci responsible for the utilization of plant-derived glycans, such as pectic polysaccharides and xyloglucans, and the foraging activity of these bacteria allows them to thrive in the gut ecosystem 8) . Our group reported the isolation of the genes encoding 1,2-α-L-fucosidase and endo-α-N-acetylgalactosaminidase from bifidobacteria in 2004 and 2005, respectively 9, 10) . Both enzymes act on host-derived glycans, including milk oligosaccharides and mucin glycoproteins, and interestingly, the homologues of these enzymes were found to be conserved in particular gut microbes 11) . Based on these findings, we envisaged that the host-derived glycans are also an important and influential factor for the microbial composition in the gut 11) (Note that a host genetic factor, e.g. secretor or non-secretor, has been recently shown to affect gut microbiota composition 12) ).
The composition of human gut microbiota changes during life, and the most drastic adaptations occur at the start of breast-feeding and the end of it, i.e., during weaning 13, 14) .
The intestines of breast-fed infants are rapidly and dominantly colonized by bifidobacteria within a week after birth, and the bifidobacteria-rich population drastically decreases after weaning 15, 16) . This observation strongly suggests that human milk contains compounds (perhaps, host-derived glycans) that selectively stimulate the growth of bifidobacteria in the infant gut. The presence of bifidobacteria in the gut microbiota appears to be correlated with a reduced incidence of diseases such as diarrhea and allergies in infants 17) . Various beneficial effects of bifidobacteria on host health have been reported, including the inhibition of harmful bacteria 17) , fortification of barrier function of intestinal epithelial cells 18) , and modulation of immune function 19) . Thus, the bacteria might be the first evolutionary commensals in the human gut, but the molecular mechanism underlying the formation of bifidobacteria-rich microbiota in the intestines of breast-fed infants remains elusive. In this review, I summarize the advances made by our group over the past 10 years on bifidobacterial enzymes that are dedicated to the degradation of human milk oligosaccharides (HMOs; see section III for definition), in the context of the historical research efforts on bifidobacteria and HMOs. The structurefunction analysis of the bifidobacterial enzymes indicates a symbiosis and co-evolution between bifidobacteria and humans.
II. Historical background Bifidobacterium sp. (first named Bacillus bifidus communis) was isolated in 1899
from the feces of breast-fed infants by H. Tissier at the Pasteur Institute. He already mentioned at the time that the gut microbiota of breast-fed infants are richer in bifidobacteria as compared to the feces of bottle-fed infants 20) . Although the ratio of occupancy varies in different studies and with different detection techniques (culture method vs. non-culture method), it is currently well established that an increased population of bifidobacteria and a decreased population of other, especially pathogenic, bacteria, are specific features of the intestinal microflora of breast-fed babies [13] [14] [15] . The finding that bifidobacteria are predominantly present in the gut of breast-fed newborns and that the bacteria showed enhanced growth on media supplemented with human, but not cow, milk 20, 21) , convinced researchers that human milk contains bifidogenic compounds (or bifidus factors).
In 1954, Gauhe et al. reported that the oligosaccharides in human milk have a bifidogenic effect 22) . They partially purified the relevant oligosaccharides and found they consisted of L-fucose (Fuc), galactose (Gal), glucose (Glc), and N-acetylglucosamine (GlcNAc). The concept that HMOs acted as bifidus factors was attractive. However, the interpretation of these experiments was later disputed, because they used a variant strain of Bifidobacterium sp. (Bifidobacterium bifidum var. pennsylvanicus) that was probably impaired in its ability to synthesize GlcNAc-containing cell-wall components 22, 23) . It should be mentioned, however, that most bifidobacteria do not utilize exogenously added GlcNAc efficiently 24) . Therefore, the above observation should not be attributed to misuse of the variant strain only. Indeed, Gauhe et al. mentioned in their paper that many bifidobacterial strains isolated from the breast-fed infants showed the same phenotype as Bifidobacterium bifidum var. pennsylvanicus 21) . 25) , and Crane et al. found that HMOs block the binding of enterotoxins of
Escherichia coli to intestinal cells 26) . Reduction of the binding of human immunodeficiency virus-1 to dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin was also reported 27) . In addition, disialyllacto-N-tetraose was shown to ameliorate necrotizing enterocolitis in rats 28) . These studies, combined with a continuous advance of analytical instruments, have become the driving force to decipher various biological functions of HMOs.
III. Human milk oligosaccharides (HMOs)
Oligosaccharides (with a degree of polymerization of more than 3) are the third most abundant solid component in human milk (between 10 and 20 g/L), after lactose (Lac) and lipids, and they are collectively termed HMOs 29) . HMOs are characterized by their complex structures, and more than 200 molecular species have been detected 30) .
They are divided into 13 core structures that consist of Lac at the reducing end, elongated by β1-3-linked lacto-N-biose I (Galβ1-3GlcNAc: LNB, type-1 chain) and/or β1-3/6-linked N-acetyllactosamine (Galβ1-4GlcNAc: LacNAc, type-2 chain). The core structures are frequently modified by Fuc and sialic acid (Neu5Ac) via α1-2/3/4 and α2-3/6 linkages, respectively, to more complex structures 31) . Among these HMOs, lacto-N-
, and 2′-fucosyllactose (2′-FL, Fucα1-2Galβ1-4Glc) are the most abundant, especially in the colostrum, unless the milk is derived from non-secretor and/or Lewis-negative subjects ( Fig. 1 ) 29, 31) . It should be noted that HMOs are especially rich in type-1 chains, as is the case for three of the above structures (LNT, LNFP I, and LNDFH I), as this composition is unique for human milk oligosaccharides 29) . The type-1 richness of HMOs constitutes one of the rationales behind 6 the concept of symbiosis and co-evolution between bifidobacteria and humans, details of which are described in sections IV and V.
Considering the mother's energy expenditure to synthesize 10−20 g/L of HMOs in the mammary glands (one ATP is theoretically consumed per elongation of one sugar residue), they should represent a relevant biological advantage to infants 32) . One important activity of HMOs is, as mentioned above, to defend neonates from infectious disease. HMOs are resistant to the host's intestinal digestive enzymes 33) , and thus the majority should reach the colon, where they exert their activity. Another activity of HMOs is the modulation of immune responses 17, 19) . A small amount of HMOs is detected in the urine and plasma of infants, sometimes modified by acetylation and further glycosylation 34, 35) . He et al. showed that 2′-FL can attenuate the lipopolysaccharideinduced inflammatory response of intestinal epithelial cells in vitro 36) . As discussed in this review, one of the most important activities of HMOs is to enhance the development of a bifidobacteria-rich microbial population, by acting as their preferred nutrient. Infantgut associated bifidobacteria possess the specific genetic and enzymatic toolsets dedicated to the assimilation of HMOs.
IV. Specific occurrence of HMO-degrading enzymes in infant gut-associated bifidobacteria
Bifidobacterium breve, B. bifidum, B. longum subsp. infantis (referred to as B.
infantis), and B. longum subsp. longum (B. longum) are four well-known species/subspecies found in the stool of breast-fed babies 15, 37) . In 1999, Derensy-Dron et al. reported the presence of a phosphorylase specific for galacto-N-biose (GNB, Galβ1-3GalNAc) and lacto-N-biose I (LNB, Galβ1-3GlcNAc) in B. bifidum 38) . The enzyme catalyzes the phosphorolysis of GNB and LNB to produce α-D-galactose 1-phosphate and the respective N-acetylhexosamines. Subsequently, Kitaoka et al. isolated the corresponding gene from B. longum and fully characterized the enzyme 39) . GNB is the disaccharide liberated from core-1 type O-glycan (Galβ1-3GalNAcα-O-Ser/Thr) by endo-α-N-acetylgalactosaminidase (isolated from B. longum) (see Section I) 10) . Given that GNB/LNB phosphorylase (GLNBP) is located in the cytoplasm while endo-α-Nacetylgalactosaminidase is cell-wall-anchored with its catalytic domain exposed to the outer surface, the liberated GNB needs being imported by a specific transporter. Not . Kitaoka et al. thus proposed that LNB is a bifidus factor 39) . Accordingly, the molecular cloning of 1,2-α-L-fucosidase, endo-α-Nacetylgalactosaminidase, and GLNBP became an important clue to elucidate the disputed role of HMOs as bifidus factors. In the following sections, I shortly describe the key enzymes required to degrade the three main components of type-1 HMOs (LNT, LNFP I, and LNDFH I) (Fig. 1) .
Lacto-N-biosidase (LNBase)
Twenty eight bacterial species/subspecies belonging to the Bacteroides,
Bifidobacterium, Clostridium, Enterococcus, Eubacterium, Lactobacillus, and
Ruminococcus genera, which constitute main human gut microbiome, were examined for their ability to liberate LNB from LNT 40) . Of these 28 (sub)species, all strains of B.
bifidum and two strains of B. longum tested positive (LNBase + ). The gene for LNBase was isolated from B. bifidum based on the sequence of the Streptomyces sp. LNBase, which was the sole enzyme identified at that time 41) . The gene, designated lnbB, was found to encode a protein of 1,112 amino acid residues with a predicted molecular mass from bacterial and mammalian sources 43, 44) . Hydrolysis by GH20 enzymes is known to proceed through a substrate-assisted mechanism, in which the N-acetyl group of the substrate (in the case of LNT, this is GlcNAc) attacks its own anomeric carbon to form an oxazoline intermediate 44) . The important catalytic residues identified in β-Hex-ases were conserved in LnbB 40) . Interestingly, while LNBase acts on β-linked LNB and to a lesser extent on β-linked GNB, it does not act on β-linked HexNAc monosaccharides. In contrast, β-HexNAc-ases act on β-linked HexNAc, but not on β-linked LNB/GNB disaccharides, even though the linkage to be hydrolyzed is the same and both enzymes belong to the same GH family 40, [43] [44] [45] . To understand the molecular basis of the substrate recognition by each enzyme and to subsequently be able to distinguish between the two at the sequence level, our group solved the crystal structure of the catalytic domain of LnbB (41-663 aa) in complex with LNB at 1.8-Å resolution (Fig. 2B) 46) . The structures of complexes with competitive inhibitors with Ki values of 0.1-50 µM have recently also been determined 47) . As shown in the molecular surface models of the two enzymes (B.
bifidum LnbB and human β-HexNAc-ase) 45) , LNBase possesses an extended pocket (-2 subsite) suitable for accommodating the β-(1→3)-linked Gal residue of LNB (Fig. 2C) , and forms several hydrogen bonds with Gal 46) . In contrast to LNBase, Hsβ-HexNAc-ase possesses a catalytic pocket that can accept one HexNAc residue and the corresponding site (Gal-binding site of LNBase) is occupied by the residues extending from the β1 and β2 sheets and the following loop region, which become a steric hindrance for the accommodation of LNB. LNBase lacks a residue that recognizes the O3 atom of -1 GlcNAc, which could prevent it from forming a stable transition-state intermediate in the absence of the -2 Gal residue, leading to the loss of HexNAc-ase activity. As this information provided us with a rationale for how the two enzymes differently recognize their respective substrates, we were able to discriminate between the two enzymes at the amino acid sequence level. The homologues of LnbB (i.e. LNBase, not β-HexNAc-ase) are found in the genomes of B. bifidum (all of the sequenced strains), Trueperella pyogenes (an isolate from bovine mastitis), Actinomyces neuii (an isolate from mammary prosthesis), Chlamydia trachomatis, and some species of Streptomyces, which indicates the specific presence of LNBase in bifidobacteria. The structural studies also suggested that LNBase evolved from β-HexNAc-ase.
The genome sequence of B. longum JCM1217 became publicly available in 2011 48) .
Although the strain was shown to be phenotypically LNBase + , no homologous gene to lnbB of B. bifidum was found. The gene product containing the GH20 domain was identified to be β-GlcNAc-ase 49) . Expression cloning was carried out to isolate the LNBase gene from the strain, and consequently, locus_tag BLLJ_1505 and BLLJ_1506
were identified 50) . BLLJ_1505 (termed LnbX) showed no sequence similarity to the previously characterized proteins but was found to possess a signal peptide ( LnbY did not contain any metal ion. The lnbX and lnbY genes constitute an operon, as the polar effect was observed when the lnbX gene was disrupted in B. longum 50) . The substrate specificity of LnbX was also found to be unique. Although GH20 LnbB is active on the unmodified LNB structure (e.g. LNT), LnbX was able to hydrolyze LNFP I and sialyllacto-N-tetraose a (LST a) to release 2′-fucosyl LNB and 3′-sialyl LNB, respectively.
However, the activities are considerably lower than that for LNT, and therefore not physiologically relevant ( Table 1 . See section V). Moreover, LnbX was found to act on the β-linked GNB present in sugar chains of globosides (Gb5 and globo H), but it was inactive on GA1 tetrasaccharide in which β-GNB is linked with the axial O4 of the Gal residue. GH20 LnbB was capable of acting on GA1 and Gb5 oligosaccharides but not on globo H hexasaccharide 51) . LnbX homologues are found in the genomes of gut microbes belonging to Bifidobacterium, Roseburia, Eubacterium, Ruminococcus, and Clostridium, whereas LnbY homologues are found only in B. longum and B. bifidum (note that LnbY homologues of B. bifidum lack a signal sequence) 52) . Considering the unique maturation process of LnbX and LnbY, it should be empirically determined whether these homologues have LNBase activity. Structural studies of LnbX and LnbY are currently ongoing, which will help us understand the unique features of these two enzymes.
Galacto-N-biose/lacto-N-biose I transporter (GNB/LNB transporter)
As mentioned above, the genes for an ABC transporter were found to be located just upstream of the GNB/LNB phosphorylase (GLNBP) gene in the B. longum genome 39) .
When they were introduced into B. longum strain 105-A on a plasmid, the resulting strain was found to show a 10-fold increase in the uptake of ( 14 C-labelled) LNB as compared with the control strain carrying an empty plasmid (unpublished results). This indicates the direct involvement of the genes in LNB transport. The substrate specificity of the ABC transporter is primarily defined by the solute-binding protein, and therefore we purified and characterized the corresponding protein of the transporter 53) . The purified protein (termed GL-BP) was shown by isothermal calorimeter analysis to specifically bind GNB and LNB with a Kd value of 10 and 87 nM, respectively. The protein had a low affinity for LNT (Kd of 11 µM), but it was completely heat silent towards monosaccharides constituting the disaccharides (i.e. Gal, GlcNAc, and GalNAc), and disaccharides Lac and LacNAc (type-2 chain). The binding was enthalpy-driven with a slight negative entropy change. Subsequent X-ray structural analysis revealed that the binding was primarily dependent on hydrogen bonds. Interestingly, the axial O4 of the GalNAc residue of GNB forms a water-mediated hydrogen bond with the GL-BP protein, which is absent in the LNB-complex. This might correspond to the difference in enthalpy change in the binding of the two ligands (8 kcal/mol) 53) . .
Lacto-N-tetraose β-1,3-galactosidase (LNT-Gal-ase)
In 2008, Sela et al. determined the genomic sequence of B. infantis 55) . They found that this subspecies has a gene cluster dedicated to the degradation of HMOs (termed HMO cluster-1) on its genome and hypothesized that the presence of this cluster is linked to the ability of the respective strains to grow on HMOs. Interestingly, none of the glycosidases encoded in the cluster were found to possess a signal sequence. Therefore, Sela et al. predicted that the organism imports intact HMOs into the cytoplasm prior to degradation 55) . Indeed, when B. infantis cells were incubated with LNT, the tetrasaccharide disappeared from the culture supernatant, and during the incubation period, no mono-, di-, and trisaccharides appeared in the spent medium 56) . The uptake involves an ABC transporter, as the activity was completely abolished in the presence of an ABC transporter inhibitor. Degradation of LNT by B. infantis inside the cells involves monosaccharide-releasing exo-glycosidases because liberation of Gal, GlcNAc, and Glc was observed when LNT was incubated with the cell-free extract. This was an intriguing finding because the β-galactosidase (β-Gal-ase) located in the HMO cluster-1 was considered to be specific for type-2 chains as it belongs to GH2 42) . Taking these findings into consideration, the genome of this subspecies was scrutinized, and 6 candidate genes were isolated and the recombinant proteins were characterized enzymatically. From these 6 candidates, the protein with locus_tag Blon_2016 (belonging to GH42), not located at the locus HMO cluster-1, was found to efficiently liberate Gal from LNT (kcat/Km of 120 mM -1 s -1 ) ( Table 1) , while the other enzymes, including GH2 β-Gal-ase from the HMO cluster-1, were inactive on LNT 56) . This was the second report at the time describing the isolation of a β-Gal-ase that hydrolyzes type-1 chains, and the first report to show that the GH42 enzyme degrades human-derived glycans. GH42 members had been assumed to degrade plant-derived glycans 42) . Interestingly, LNT-Gal-ase was shown to have a higher affinity for LNT than for LNB, even though the scissile bond is the same in the two substrates. Probably, the enzyme has a (+) subsite that interacts with the Lac moiety of LNT. Our results also revealed that the HMO degradation capacity of B. infantis could not be exclusively attributed to HMO cluster-1 56) .
Recent reports by Viborg et al. have shown that the substrate specificity of different GH42 enzymes is more diverse than previously anticipated based on their phylogenetic distances (Fig. 3A ) 57, 58) . For example, the amino acid sequence of Gal-ase (locus_tag Balac_0484, termed BlGal42A) from B. animalis subsp. lactis is 62% identical to that of LNT-Gal-ase of B. infantis. Nonetheless, it hardly acts on LNT (Fig. 3B) but shows a preference for galactooligosaccharides with β-(1→6/3) linkages 57) . On the other hand, B. bifidum β-Gal-ase, which is 74% identical to B. infantis LNT-Gal-ase, was found to be capable of hydrolyzing LNT although its efficiency is less than that of the B. infantis enzyme (Fig. 3B) . Structural studies are necessary to understand the molecular basis of the differential substrate recognition by these similar enzymes at the (+) subsites. From bacteria to humans, only four enzymes (all GH35 and GH42 members) have been reported so far to act on type-1 chains, suggesting that this type of activity is quite rare in nature 42) . Homologues (> 74% identity) of LNT-Gal-ase of B. infantis were found exclusively in infant gut-associated bifidobacteria (B. longum, B. bifidum, B. breve, and B. infantis) (Fig. 3A) .
Our group also enzymatically and structurally characterized 1,2-α-L-fucosidase fucosidase that requires a branched Gal residues has been identified by x-ray structural studies 62, 63) . Lactobacillus casei has a cytoplasmic α-L-fucosidase specific for Fucα1-3GlcNAc disaccharides 64) . However, it remains to be elucidated whether this enzyme is involved in HMO degradation because action of this enzyme on HMO structures requires prior removal of Gal residues.
Taken together, these findings suggest that infant gut-associated bifidobacteria have evolved specific enzymes dedicated to the degradation of type-1 HMOs. The metabolic process of LNB inside the cells has been summarized by Kitaoka 65) . The limited occurrence of the homologues of HMO-degrading enzymes in bifidobacteria has also been reported by Odamaki et al. 66) . , and not much later also by Marcobal et al. 69) . By analyzing the oligosaccharides present in the spent media by mass spectrometry, these authors found that B. infantis can consume a range of HMO structures, thetaiotaomicron cultures, a small amount of the trisaccharide lacto-N-triose II (GlcNAcβ1-3Galβ1-4Glc) was identified. Given these results, we examined the in vitro fermentation ability of infant gut-associated bifidobacteria and precisely determined the metabolic fate of each of the neutral HMOs during cultivation, by using HPLC to detect 2-anthranilic-acid-labelled sugars 24) . The merits of HPLC detection of fluoresceinlabelled sugars over mass spectrometry are (1) highly sensitive quantification of sugars (mono-and oligosaccharides), and (2) reliable isomer separation (type-1 versus type-2).
V. Consumption of HMOs by infant gut-associated bifidobacteria
When the selected strains of infant gut-associated bifidobacteria were incubated in medium containing HMOs as the carbon source, B. bifidum JCM1254 and B. infantis JCM1222 showed vigorous growth (OD600 > 1.5). The growth of B. breve JCM1192 and B. longum JCM1217 was significantly lower, as the OD600 value never exceeded 0.4.
HPLC analysis of the mono-and oligosaccharides in the spent media revealed that B.
breve JCM1192 and B. longum JCM1217 consumed LNT only (Fig. 4) . B. longum used lacto-N-biosidase (LnbX) to degrade LNT, as a transient increase in Lac accompanied the decrease in LNT. A slight decrease in LNFP I was observed, which reflects the substrate specificity of LnbX, but this decrease seemed not physiologically relevant. LNB was not detected during this period, suggesting that B. longum prefers LNB over Lac. In contrast, B. breve appeared to consume LNT without hydrolyzing it outside the cells. In other words, B. breve directly imported the tetrasaccharide, because no mono-or di-saccharide degradation products were detected. In accordance, neither LNT-Gal-ase nor LNBase activity was detected in the extracellular fraction of B. breve JCM11192. The genomes of the 7 strains of this species do not possess homologues for the secretory β-galactosidase or for LNBase 52) .
As expected, B. infantis imported a wide variety of intact HMOs (Fig. 4) . All oligosaccharides disappeared when the organism entered the logarithmic phase, which was followed by a temporal increase in a small amount of monosaccharides (Fuc, Gal, and Glc). The transient increase of monosaccharides might be a counteraction against the osmotic pressure caused by the rapid uptake of large amounts of HMOs. The HMO consumption behavior of B. infantis is consistent with the metabolic ability deduced by the genomic analysis 55) . . B. infantis is equipped with all types of glycosidases required to hydrolyze the linkages of HMOs in its cytoplasm, and thus consumed all HMOs from the medium 55, 56, 62) . B. bifidum, another avid HMO consumer, was found to degrade HMOs in a different manner. As 1,2-α-L-fucosidase, 1,3-1,4-α-L-fucosidase, and LNBase of B. bifidum are secretory enzymes 9, 62) , the organism degraded HMOs into mono-and disaccharides extracellularly. Unexpectedly, this degradation occurred before the species entered the exponential growth phase (Fig. 4) . The degraded mono-(Fuc, Gal, and Glc) and disaccharides (LNB and Lac) were abundantly present in the culture medium of B. bifidum between the early and mid-logarithmic phases 24) . Even after degrading all kinds of HMOs and entering the stationary phase, monosaccharides remained unconsumed. Similar to B. longum, B. bifidum also has a preference for LNB over Lac.
Nonetheless, the LNB concentration (1.3 mM) at the lag phase (before entering logarithmic phase) reached to half of the sum of the initial concentrations of LNT and LNFP I. The Lac concentration became equal to the sum of LNT and LNFP I. These results suggest that these metabolites are shared among gut microbes, especially among bifidobacteria 24) . Importantly, the GNB/LNB transporter, GNB/LNB phosphorylase (GLNBP), and LNB assimilation ability are limited to infant-gut-associated bifidobacteria 71, 72) . B. infantis appears to be 'selfish' in utilizing HMOs, while B. bifidum is 'altruistic'. It is interesting to note that Tannock et al. found that the population and diversity of bifidobacteria increase significantly when B. bifidum occupies > 10% of the total bifidobacterial counts in infant feces, as compared with the case that B. bifidum population counts for less than 10% 37) . They also mentioned that this phenomenon only occurs in breast-fed babies, strongly suggesting the symbiotic sharing of HMOs among bifidobacteria.
B. infantis and B. bifidum were able to consume type-2 HMOs efficiently 24, 73) . The hydrolysis of type-2 oligosaccharides occurs respectively inside and outside of B. infantis and B. bifidum cells. Our group has already identified β-galactosidase that specifically acts on lacto-N-neotetraose (Galβ1-4GlcNAcβ1-3Galβ1-4Glc) 56) and β-HexNAc-ase that is highly specific for lacto-N-triose II (GlcNAcβ1-3Galβ1-4Glc) 73) .
VI. Concluding remarks
The gut microbial population of breast-fed infants constitutes a tripartite relationship between the mother's milk, the infant, and bacteria. In general, bifidobacteria constitute a larger part of the microbiota of breast-fed newborns than of that of bottle-fed babies [13] [14] [15] . Albrecht et al. examined the profiles of the oligosaccharides present in the milk of breast-feeding mothers and the feces of the corresponding infants and found that the HMO degradation in the infant's digestive tract is highly variable 74) . In one case, an oligosaccharide lacking the LNB moiety of fucosyllacto-N-hexaose II was identified in the infant feces (and was not present in the mother's sample), which strongly suggests the action of LNBases in the intestine of the infant. In the same sample, a reduction in fucosylated oligosaccharides and LNT was observed. Although the oligosaccharide profile in milk did not change significantly during the first six months after giving a birth, the profiles of infant feces showed drastic changes. This indicates that the changes in oligosaccharide degradation in the infant digestive tract are linked with a maturation process of gut microbiota 74) . De Leoz et al. have recently confirmed that infants with bifidobacteria-rich gut-microbiota exhibit a more extensive HMO degradation in their feces than infants with microbiota with less bifidobacteria, although this study only compared the feces of two babies 75) . In combination with the above mentioned our findings, it is therefore highly likely that HMOs serve to stimulate the growth of bifidobacteria to dominate the infant gut microbial population.
In retrospect, the 1954 report by Gauhe et al. describing oligosaccharides consisting of Fuc, Gal, Glc, and GlcNAc that act as bifidus factor was fairly accurate 22) . Although their results were dismissed based on the use of a variant (perhaps, mutant) strain of bifidobacteria, they already mentioned that bifidobacterial strains with the same phenotype (i.e. requiring HMOs for rapid growth, but not cow milk) were frequently isolated from the stool of breast-fed babies. Unfortunately, these pioneering findings could not be validated at the time because of a lack of genetic and analytical tools. In addition, it was difficult to conceive that the specific assimilation of HMOs by bifidobacteria involves and relies on the uptake of di-or longer saccharides (LNB, LNT, LNFP I etc.).
HMOs have no apparent nutritional value for infants, even though they are the third most abundant component in human milk. Nevertheless, human females have evolved to produce a large amount of HMOs (10-20 g/L) in the mammary glands at a great expense of energy 29) . Apart from the structural diversity among mammals, milk oligosaccharides also appeared in monotreme species (platypus and echidna) 76) . Urashima et al. have claimed that the original function of milk oligosaccharides is the prevention of microbial infection (HMOs also work in that way), and that the roles of milk oligosaccharides have diversified later during evolution 76) . In a rare case of cross-kingdom symbiosis, humans and bifidobacteria might have succeeded in mutually exploiting HMOs as beneficial compounds, as deduced by the fact that the presence of type-1 chain-specific enzymes is limited to infant gut-associated bifidobacteria and that only human milk is rich in type-1 chain oligosaccharides.
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